From the Departments of Pediatrics School of Medicine, Tehran University of Medical Sciences, Tehran, I.R. Iran.
Abstract: (4349 Views)
In order to determine the efficacy of recombinant hepatitis B vaccine in Iranian
infants, we analyzed the efficacy of a recombinant hepatitis B vaccine in 115
infants aged 12-24 months born to HBsAg negative mothers who received three
doses of HBV Antibody to hepatitis B surface antigen (anti-HBs) was checked
after the third dose of the vaccine, 94.8% of the infants had developed protective
antibody levels. The vaccine was well-tolerated and no serious adverse effects
were reported.
This study is in agreement with a WHO report which recommends that the
easiest and most cost-effective strategy for the control and eventual eradication of
HBV would be to immunize all newborns with hepatitis B vaccine only [World
Health Organization report, 1984].
Type of Study:
Original Research |
Subject:
Pediatric